Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Thermo Fisher Reports Strong Q3 Growth Amid New Product Launches and Approvals

Thermo Fisher Scientific, a leading biopharma service provider and supplier, has reported a 5% year-over-year increase in sales for the third quarter of 2025, generating $11.12 billion in revenue. The company's growth strategy appears to be paying dividends, with recent product launches and regulatory approvals contributing to its positive financial performance.

NoahAI News10/22/2025

Terns Pharmaceuticals Halts Obesity Program as Phase 2 Results Disappoint

Terns Pharmaceuticals has announced the discontinuation of its oral GLP-1 obesity candidate, TERN-601, following disappointing results from a phase 2 clinical trial. The decision marks a significant setback for the company's metabolic disease portfolio and highlights the intensifying competition in the oral GLP-1 market.

NoahAI News10/22/2025

Johnson & Johnson Navigates Stelara Patent Cliff, Unveils Growth Strategy

Johnson & Johnson (J&J) has successfully steered through the loss of exclusivity for its blockbuster drug Stelara, demonstrating resilience and strategic acumen in the face of significant market challenges. The pharmaceutical giant's multifaceted approach to maintaining growth amid the erosion of a cornerstone product offers valuable insights into the industry's dynamics and J&J's future trajectory.

NoahAI News10/22/2025

Novo Nordisk Foundation Overhauls Board, Signaling Major Shift in Leadership and Strategy

Novo Nordisk, the Danish pharmaceutical giant, is undergoing a significant leadership transformation as its main shareholder, the Novo Nordisk Foundation, pushes for aggressive changes to revitalize the company's fortunes. This move comes amid growing concerns over the company's performance in the highly competitive obesity and diabetes drug market.

NoahAI News10/22/2025

Neuphoria's Social Anxiety Drug Fails Phase III Trial, Company Initiates Strategic Review

Neuphoria Therapeutics announced that its lead candidate for social anxiety disorder, BNC210 (soclenicant), failed to meet its primary endpoint in a late-stage clinical trial. The disappointing results have prompted the company to discontinue its social anxiety disorder program and launch a strategic review of its business operations.

NoahAI News10/22/2025

Galapagos Winds Down Cell Therapy Business, Cuts 365 Jobs Amid Industry Shifts

Galapagos NV, a Belgian biotechnology company, has announced plans to wind down its cell therapy business after failing to secure viable offers for the unit. This strategic shift comes amid broader changes in the cell therapy landscape, with other major pharmaceutical companies also retreating from the field.

NoahAI News10/22/2025

Vertero Therapeutics Emerges with New Focus and $20M Funding for Neurodegenerative Disease Research

Axial Therapeutics, a biotech company previously focused on autism-related therapies, has reemerged after a two-year hiatus with a new identity and mission. Now known as Vertero Therapeutics, the company has secured $20 million in Series D funding to support its renewed focus on neurodegenerative diseases, particularly Parkinson's disease.

NoahAI News10/22/2025

FDA Reports Death in Patient on Ascendis Pharma's Yorvipath, Raising Safety Concerns

The pharmaceutical industry faces renewed scrutiny as the U.S. Food and Drug Administration (FDA) reports a patient death associated with Ascendis Pharma's hypoparathyroidism drug, Yorvipath. This development has sent ripples through the market and raised questions about the drug's safety profile.

NoahAI News10/22/2025

Highmark Health and Noom Launch Innovative Weight Management Partnership

Highmark Health, a major healthcare provider and insurer, has announced a groundbreaking partnership with digital health platform Noom to offer comprehensive weight management support to its members. The collaboration, unveiled at the HLTH 2025 conference in Las Vegas, aims to address rising healthcare costs associated with obesity and related conditions.

NoahAI News10/22/2025

Novo Nordisk Board Shakeup Signals Major Strategic Shift

In a surprising turn of events, Novo Nordisk, the Danish pharmaceutical giant, has announced a significant overhaul of its board of directors. This move comes amid ongoing challenges in the competitive GLP-1 market and recent organizational restructuring.

NoahAI News10/22/2025

Pharmaceutical Industry Roundup: Major Investments, Collaborations, and Drug Approvals

Merck & Co. has broken ground on a new $3 billion manufacturing facility in Elkton, Virginia, marking a significant expansion of its domestic production capabilities. The 400,000-square-foot site, dubbed a "Center of Excellence," will produce both active pharmaceutical ingredients and drug products. This facility is part of Merck's broader $70 billion investment initiative to bolster U.S. manufacturing and R&D operations, which began in early 2025.

NoahAI News10/22/2025

Hologic to Go Private in $18.3 Billion Acquisition by Blackstone and TPG

In a significant development for the medical technology sector, Hologic, a leading manufacturer of diagnostic tools, has agreed to be acquired by private equity firms Blackstone and TPG in a deal valued at up to $18.3 billion. The transaction, which will take the company private, marks a pivotal moment in the industry and reflects growing interest from private equity in the healthcare technology space.

NoahAI News10/22/2025

«1...13 14 15...67 »